Specify a stock or a cryptocurrency in the search bar to get a summary
Hua Medicine
HUMDFHua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China. Address: Building 2, Lane 36, Shanghai, China, 201203
Analytics
WallStreet Target Price
27.91 HKDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HUMDF
Dividend Analytics HUMDF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HUMDF
Stock Valuation HUMDF
Financials HUMDF
Results | 2019 | Dynamics |